Liminatus Pharma, Inc.
LIMN
$3.84
$0.205.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -25.24% | 86.24% | -348.00% | -1,709.36% | 134.60% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | -28.57% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 321.43% | -99.94% | 570.10% | 186.90% | -- |
| Change in Net Operating Assets | 146.76% | -330.06% | 227.12% | 101.55% | -4,657.47% |
| Cash from Operations | 51.87% | -421.02% | 35.60% | 93.19% | -5,431.05% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | 65.22% |
| Cash from Investing | -- | -- | 100.00% | 93.45% | 65.22% |
| Total Debt Issued | -- | -- | -- | -100.00% | 408.70% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.93% | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | -42.00% | -- | -- | -100.00% | 1,347.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -29.34% | 505.89% | 36.97% | -147.09% | 6,190.19% |